Can Serum be Used for Analyzing the KRAS Mutation Status in Patients with Advanced Colorectal Cancer?
Seung-Tae KIM; Won-Jin CHANG; Lihua JIN; Jae-Sook SUNG; Yun-Ji CHOI; Yeul-Hong KIM.
Cancer Research and Treatment
; : 796-803, 2015.
Artículo en Inglés | WPRIM | ID: wpr-90560
Documentos relacionados
Multiplexed 3D atlas of state transitions and immune interaction in colorectal cancer.
Immunological and prognostic significance of tumour necrosis in colorectal cancer.
Subtyping and prognostic model construction based on vesicle-mediated transport-related genes in colorectal cancer.
Anti-PD-1 therapy for advanced colorectal cancer based on intestinal microecology.
Colorectal cancer clocks in on TIME.
Construction of an immune predictive model and identification of TRIP6 as a prognostic marker and therapeutic target of CRC by integration of single-cell and bulk RNA-seq data.
Evaluating mismatch repair deficiency in colorectal cancer biopsy specimens.
Cathepsin C promotes colorectal cancer metastasis by regulating immune escape through upregulating CSF1.
Development and validation of epigenetic modification-related signals for the diagnosis and prognosis of colorectal cancer.
Development of 14-gene signature prognostic model based on metastasis for colorectal cancer.